Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Mantle Cell Lymphoma: a Systematic Review and Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 23

PMID 39308870

Authors

Haixiang Wan

Songqin Weng

Sumei Sheng

Zilin Kuang

Qingming Wang

Linhui Hu

Affiliations

Soon will be listed here.

Abstract

Background: Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) were conducted. However, data on clinical safety and efficacy are inconsistent. In this study, we aimed to conduct a systematic analysis of the effectiveness and safety of CAR-T therapy across a wider and more representative cohort of patients with R/R MCL.

Methods: We performed a systematic review and meta-analysis of studies on patients with R/R MCL who received CAR-T cell therapy. Data were extracted and consolidated, with primary focus on the evaluation of safety and efficacy outcome measures. This study has not been registered with PROSPERO.

Results: This meta-analysis identified and included 16 studies with 984 patients. The pooled estimate for overall response rate (ORR) was 89%; complete remission (CR) rate was 74%. The 6-month and 12-month progression-free survival (PFS) rates were 69% and 53%, respectively, while the overall survival (OS) rates were 80% and 69%, respectively. Cytokine release syndrome (CRS) of grade 3 or higher was observed in 8% of patients, whereas neurotoxicity of grade 3 or higher was observed in 22% of patients. The risk of bias was assessed as low in 9 studies and moderate in 7 studies.

Conclusion: CAR-T therapy exhibited promising efficacy and manageable adverse reactions in patients with R/R MCL.

References

Lee Y, Jung Y, Cho J, Ko Y, Kim W, Kim S . A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma. Blood Res. 2023; 58(4):208-220. PMC: 10758639. DOI: 10.5045/br.2023.2023208. View

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

Iacoboni G, Rejeski K, Villacampa G, van Doesum J, Chiappella A, Bonifazi F . Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022; 6(12):3606-3610. PMC: 9631549. DOI: 10.1182/bloodadvances.2021006922. View

Rusconi C, Cheah C, Eyre T, Tucker D, Klener P, Gine E . Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022; 140(17):1907-1916. DOI: 10.1182/blood.2022015560. View

OReilly M, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B . Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis. Hemasphere. 2024; 8(6):e87. PMC: 11170269. DOI: 10.1002/hem3.87. View

Ryan C, Zon R, Redd R, Fisher D, Shouval R, Kumar A . Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023; 203(5):774-780. PMC: 10843463. DOI: 10.1111/bjh.19037. View

Banerjee T, Newman M, Chen A, Maziarz R, Schachter L, Spurgeon S . A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2023; 64(8):1472-1475. DOI: 10.1080/10428194.2023.2212098. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Wang M, Siddiqi T, Gordon L, Kamdar M, Lunning M, Hirayama A . Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2023; 42(10):1146-1157. PMC: 11741176. DOI: 10.1200/JCO.23.02214. View

10.

Eyre T, Cheah C, Wang M . Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood. 2021; 139(5):666-677. PMC: 9710495. DOI: 10.1182/blood.2021013326. View

11.

Arun Kumar S, Gao J, Patel S . The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma. Leuk Res. 2023; 134:107385. PMC: 10888497. DOI: 10.1016/j.leukres.2023.107385. View

12.

Rai S, Tanizawa Y, Cai Z, Huang Y, Taipale K, Tajimi M . Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. Adv Ther. 2022; 39(10):4792-4807. PMC: 9464745. DOI: 10.1007/s12325-022-02258-3. View

13.

Minson A, Dickinson M . Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024; 65(5):546-547. DOI: 10.1080/10428194.2024.2320833. View

14.

Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B . KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-1342. PMC: 7731441. DOI: 10.1056/NEJMoa1914347. View

15.

Jain P, Wang M . Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022; 97(5):638-656. DOI: 10.1002/ajh.26523. View

16.

Wang Y, Jain P, Locke F, Maurer M, Frank M, Munoz J . Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41(14):2594-2606. PMC: 10489553. DOI: 10.1200/JCO.22.01797. View

17.

McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D . Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2022; 64(2):371-377. DOI: 10.1080/10428194.2022.2148211. View

18.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

19.

Hess G, Dreyling M, Oberic L, Gine E, Zinzani P, Linton K . Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2023; 65(1):14-25. DOI: 10.1080/10428194.2023.2268228. View

20.

Minson A, Hamad N, Cheah C, Tam C, Blombery P, Westerman D . CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2023; 143(8):673-684. DOI: 10.1182/blood.2023021306. View